Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer

Journal of Urology

Volumn 190, Issue 5, 2013, Pages 1742-1749

  Loeb, Stacy ^a   Berglund, Anders ^c   Stattin, Pär ^b,d  

^a NEW YORK UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

Prostatic neoplasms; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER RISK; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; DISEASE SURVEILLANCE; EDUCATION; GLEASON SCORE; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MARRIAGE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; SWEDEN; TREATMENT DURATION; UNITED STATES; WATCHFUL WAITING;

EID: 84888639235     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.05.054     Document Type: Article

References (23)

1. Schröder FH, Hugosson J, Roobol MJ et al: Prostate-cancer mortality at 11 years of followup. N Engl J Med 2012; 366: 981.
2. Ganz PA, Barry JM, Burke W et al: National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 2012; 156: 591.
3. Cooperberg MR, Broering JM, Kantoff PW et al: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol, suppl., 2007; 178: S14.
4. Daskivich TJ, Chamie K, Kwan L et al: Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011; 117: 2058.
5. Xu J, Dailey RK, Eggly S et al: Men's perspectives on selecting their prostate cancer treatment. J Natl Med Assoc 2011; 103: 468.
6. Wu X, Chen VW, Andrews PA et al: Initial treatment patterns for clinically localized prostate cancer and factors associated with the treatment in Louisiana. J La State Med Soc 2005; 157: 188.
7. Schymura MJ, Kahn AR, German RR et al: Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer 2010; 10: 152.
8. Godtman RA, Holmberg E, Khatami A et al: Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol 2013; 63: 101.
9. Stattin P, Holmberg E, Johansson JE et al: Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102: 950.
10. Huang GJ, Sadetsky N and Penson DF: Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol 2010; 183: 2206.
11. Van Hemelrijck M, Wigertz A, Sandin F et al: Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol 2012; Epub ahead of print.
12. Charlson ME, Pompei P, Ales KL et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373.
13. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Available at www.nccn.org/professionals/physician-gls/pdf/prostate. pdf. Accessed April 1, 2012.
14. McVey GP, McPhail S, Fowler S et al: Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int 2010; 106: 1161.
15. Cooperberg M, Lubeck DP, Penson D et al: Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol 2003; 170: 905.
16. Smith JA Jr: What would you do, doctor? J Urol 2009; 182: 421.
17. Hugosson J, Carlsson S, Aus G et al: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725.
18. Klotz L, Zhang L, Lam A et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126.
19. Epstein JI, Walsh PC, Carmichael M et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368.
20. Villa L, Capitanio U, Briganti A et al: The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer. J Urol 2013; 189: 854.
21. Berglund A, Garmo H, Tishelman C et al: Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol 2011; 185: 833.
22. Carter HB, Partin AW, Walsh PC et al: Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol 2012; 30: 4294.
23. O'Connor AM, Bennett CL, Stacey D et al: Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2009; 3: CD001431.